Authors
Kasım Kağan Koca, Zeyneb Nur Akçay, Gizem Kugu, Fatma Özdemir, Olcay Arman Gürer, Merve Tuzlakoğlu Öztürk, Uygar Halis Tazebay, Ali Iftikhar, Shafaat Ahmed Rabbani, Zihni Onur Çalışkaner
Published in
Molecular biology reports. Volume 53. Issue 1. Jul 10, 2026. Epub Jul 10, 2026.
Abstract
Methyl-CpG-binding domain protein 2 (MBD2) is a key epigenetic regulator implicated in tumorigenesis by repressing tumor suppressor genes by recognizing DNA methylation marks and recruiting specific histone-modifying enzymes and chromatin remodeling complexes. Although KCC-07 has been identified as a potent selective MBD2 inhibitor, its cytotoxic effects on various cancer cells remain largely unexplored. In the current study, we have examined the anti-proliferative and cytotoxic activities of KCC-07 on breast cancer (MCF-7), prostate cancer (PC-3), hepatocellular carcinoma (Huh-7), and osteosarcoma (U2-OS) cell lines, along with human skin fibroblasts (HFF-1) as a non-malignant control.
Treatment of these cells with KCC-07 induced dose- and time-dependent cytotoxicity, notably reducing viability in Huh-7 and PC-3 cells. Flow cytometry analyses revealed that KCC-07 primarily triggered necrosis in Huh-7 and apoptosis in PC-3 cells. Furthermore, KCC-07 substantially downregulated MBD2-associated oncogenic targets such as WNT1, CCND1, and ERK1/2 in Huh-7 and PC-3 cells without altering MBD2 transcription.
These findings suggest that KCC-07 elicited a considerable cytotoxicity on cancer cells, likely modulating the expression of MBD2-related genes, highlighting its potential as a candidate for cancer therapy.
PMID:
42429995
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0